Expense recognized by the Company under the related party Support Services Agreement with Bayside was as follows (in thousands): Three months ended Nine months ended September 30, September 30, 2025 …
In connection with the Securities Purchase Agreement, the Company granted Sanofi a right of first negotiation ("ROFN") for a license, grant or transfer, including by option or sale, or any rights to …
In December 2022, the Company entered into an Open Market Sales Agreement SM ("Sales Agreement") with Jefferies, as sales agent, pursuant to which the Company may offer and sell in an at-the-market o…
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the effective time of the Merger (the “Effective Time”), each share of the Company’s common stock, par v…
Reciprocal relationship from LLY graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from LLY grap…
NLRP3 inhibitor. The Company evaluated the ROFN for performance obligations under Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”) concluding that ther…
Reciprocal relationship from NBIX graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from NBIX g…
Ventyx Biosciences Inc Debt Obligations
Instrument
Description
Confidence
Evidence
VTYX-DEBT-13467
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
VTYX-DEBT
Debt stack $10.0M
90%
Market cache reports total debt of $10.0M.
Ventyx Biosciences Inc Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Ventyx Biosciences Inc.
Ventyx Biosciences Inc Ownership
Holder
Name
Confidence
Evidence
VTYX-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 7 tracked holders.
